文献速递产科生殖医学

左甲状腺素补充对亚临床甲状腺功能减退和甲状腺自身免疫女性妊娠丢失和早产的影响:系统综述和荟萃分析

Effect of levothyroxine supplementation on pregnancy loss and preterm birth in women with subclinical hypothyroidism and thyroid autoimmunity: a systematic review and meta-analysis.
PubMed 文献 · Hum Reprod Update · 2019-01-01

该系统综述和荟萃分析纳入13项研究共7970名亚临床甲状腺功能减退(SCH)和/或甲状腺自身免疫(TAI)孕妇,评估左甲状腺素(LT4)补充对妊娠丢失率(PLR)和早产率(PBR)的影响。汇总结果显示LT4补充显著降低PLR(RR=0.56,95%CI:0.42-0.75,I²=1%,12项研究)和PBR(RR=0.68,95%CI:0.51-0.91,I²=21%,8项研究)。亚组分析显示在SCH女性中LT4显著降低妊娠丢失风险(RR=0.43,95%CI:0.26-0.72,P=0.001,I²=0%)但未显著降低早产风险(RR=0.67,95%CI:0.41-1.12,P=0.13,I²=0%);在TAI女性中LT4显著降低妊娠丢失(RR=0.63,95%CI:0.45-0.89,P=0.009,I²=0%)和早产(RR=0.68,95%CI:0.48-0.98,P=0.04,I²=46%)风险。

要点

  • LT4补充显著降低SCH和/或TAI孕妇的妊娠丢失率(RR=0.56,95%CI:0.42-0.75)和早产率(RR=0.68,95%CI:0.51-0.91)。
  • SCH女性中LT4显著降低妊娠丢失风险(RR=0.43)但未显著降低早产风险(RR=0.67,95%CI:0.41-1.12)。
  • TAI女性中LT4显著降低妊娠丢失(RR=0.63)和早产(RR=0.68)风险。

核心结论

  • 该荟萃分析证实LT4补充对SCH和/或TAI孕妇有益,即降低妊娠丢失和早产风险。
  • LT4对自然妊娠和辅助生殖妊娠的不同效应提示这些女性应分别管理。
  • 由于纳入研究数量有限,尤其亚组分析,需进一步大型RCT和基础研究确认结论并阐明分子机制。

研究设计与样本

  • 系统综述和荟萃分析,检索PubMed、EMBASE、Web of Science、Cochrane对照试验注册库和Clinicaltrials.gov截至2018年4月发表的英文研究。
  • 纳入13项研究共7970名女性,其中8项为随机对照试验(RCT),5项为回顾性研究。
  • 分别分析LT4补充对SCH和TAI女性妊娠丢失率(PLR)和早产率(PBR)的汇总效应。

主要发现

  • LT4补充显著降低SCH和/或TAI女性的PLR(RR=0.56,95%CI:0.42-0.75,I²=1%,12项研究)和PBR(RR=0.68,95%CI:0.51-0.91,I²=21%,8项研究)。
  • SCH女性中LT4显著降低妊娠丢失风险(RR=0.43,95%CI:0.26-0.72,P=0.001,I²=0%)但未显著降低早产风险(RR=0.67,95%CI:0.41-1.12,P=0.13,I²=0%)。
  • TAI女性中LT4显著降低妊娠丢失(RR=0.63,95%CI:0.45-0.89,P=0.009,I²=0%)和早产(RR=0.68,95%CI:0.48-0.98,P=0.04,I²=46%)风险。
  • 仅纳入RCT时结果一致。
  • SCH女性中LT4降低辅助生殖妊娠的妊娠丢失风险(RR=0.27,95%CI:0.14-0.52,P<0.001,I²=14%)但未显著降低自然妊娠的妊娠丢失风险(RR=0.60,95%CI:0.28-1.30,P=0.13,I²=0%);TAI女性中LT4降低自然妊娠的妊娠丢失(RR=0.61,95%CI:0.39-0.96,P=0.03,I²=0%)和早产(RR=0.49,95%CI:0.30-0.79,P=0.003,I²=0%)风险但未显著降低辅助生殖妊娠的妊娠丢失(RR=0.68,95%CI:0.40-1.15,P=0.15,I²=0%)和早产(RR=1.20,95%CI:0.68-2.13,P=0.53,I²不适用)风险。

临床怎么用

  • 作者认为LT4补充对SCH和/或TAI孕妇有益,可降低妊娠丢失和早产风险。
  • 作者认为LT4对自然妊娠和辅助生殖妊娠的不同效应提示这些女性应分别管理。
  • 作者建议需进一步大型RCT和基础研究确认结论并阐明分子机制。

局限性

  • 由于纳入研究数量有限,尤其亚组分析,需进一步大型RCT和基础研究确认结论并阐明分子机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Subclinical hypothyroidism (SCH) and thyroid autoimmunity (TAI) are associated with adverse pregnancy outcomes such as pregnancy loss and preterm birth. However, the ability of levothyroxine (LT4) supplementation to attenuate the risks of these outcomes remains controversial. OBJECTIVE AND RATIONALE: This systematic review and meta-analysis was conducted to determine the effect of LT4 supplementation on pregnancy loss rate (PLR) and preterm birth rate (PBR) among pregnant women with SCH and TAI. SEARCH METHODS: A systematic literature search of the PubMed, EMBASE, Web of Science and Cochrane Controlled Trials Register databases and Clinicaltrials.gov was performed to identify all relevant English studies published up to April 2018. The following terms were used for the search: [subclinical hypothyroidism OR thyroid autoimmunity OR thyroperoxidase antibody (TPO-Ab) OR thyroglobulin antibodies (Tg-Ab)] AND (levothyroxine OR euthyrox) AND [pregnancy outcome OR miscarriage OR abortion OR pregnancy loss OR preterm birth OR premature delivery OR early labo(u)r]. The reference lists of the relevant publications were also manually searched for related studies. Published manuscripts were included if they reported data on pregnancy loss, preterm birth or both. We separately analysed the pooled effects of LT4 supplementation on PLR and PBR in women with SCH and TAI. OUTCOMES: Overall, 13 eligible studies including 7970 women were included in the meta-analysis. Eight and five of these studies were randomized controlled trials (RCTs) and retrospective studies, respectively. The pooled results indicated that LT4 supplementation significantly decreased the PLR [relative risk (RR) = 0.56, 95% confidence interval (CI): 0.42-0.75, I2 = 1%, 12 studies] and PBR (RR = 0.68, 95% CI: 0.51-0.91, I2 = 21%, eight studies) in women with SCH and/or TAI. We further found that LT4 supplementation significantly decreased the risk of pregnancy loss (RR = 0.43, 95% CI: 0.26-0.72, P = 0.001, I2 = 0%) but not of preterm birth (RR = 0.67, 95% CI: 0.41-1.12, P = 0.13, I2 = 0%) in women with SCH. Furthermore, LT4 supplementation significantly decreased the risks of both pregnancy loss (RR = 0.63, 95% CI: 0.45-0.89, P = 0.009, I2 = 0%) and preterm birth (RR = 0.68 95% CI: 0.48-0.98, P = 0.04, I2 = 46%) in women with TAI. These results were consistent when only RCTs were included in the analysis. Further, in women with SCH, LT4 supplementation reduced the risk of pregnancy loss in pregnancies achieved by assisted reproduction (RR = 0.27, 95% CI: 0.14-0.52, P < 0.001, I2 = 14%) but not in naturally conceived pregnancies (RR = 0.60, 95% CI: 0.28-1.30, P = 0.13, I2 = 0%). By contrast, in women with TAI, LT4 supplementation reduced the risks of both pregnancy loss (RR = 0.61, 95% CI: 0.39-0.96, P = 0.03, I2 = 0%) and preterm birth (RR = 0.49, 95% CI: 0.30-0.79, P = 0.003, I2 = 0%) in naturally conceived pregnancies but not in pregnancies achieved by assisted reproduction (RR = 0.68, 95% CI: 0.40-1.15, P = 0.15, I2 = 0% for pregnancy loss and RR = 1.20, 95% CI: 0.68-2.13, P = 0.53, I2 not applicable for preterm birth). WIDER IMPLICATIONS: This meta-analysis confirmed the beneficial effects of LT4 supplementation, namely the reduced risks of pregnancy loss and preterm birth, among pregnant women with SCH and/or TAI. The different effects of LT4 supplementation on naturally conceived pregnancies and pregnancies achieved by assisted reproduction in women with SCH and/or TAI suggest that these women should be managed separately. Due to the limited number of studies included in this meta-analysis, especially in the subgroup analysis, further large RCTs and fundamental studies are warranted to confirm the conclusions and better clarify the molecular mechanism underlying these associations.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Rao M, Zeng Z, Zhou F, et al. Effect of levothyroxine supplementation on pregnancy loss and preterm birth in women with subclinical hypothyroidism and thyroid autoimmunity: a systematic review and meta-analysis. Hum Reprod Update. 2019. PMID: 30951172. doi:10.1093/humupd/dmz003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。